Bristol-Myers closes on Inhibitex purchase
Quick ReadDrugmaker Bristol-Myers closes $2.5 billion deal for Inhibitex
(AP) -- Bristol-Myers Squibb Co. said late Monday that it's completed its $2.5 billion acquisition of Inhibitex Inc., a drug developer that Bristol sought as part of its strategy to become a player in the hot hepatitis C drug market.
Earlier Monday, New York-based Bristol-Myers announced it had finished its tender offer for Inhibitex stock, acquiring about 91 percent of the outstanding shares,...
